Sagimet Biosciences Inc. stock rated Strong Buy on promising drug data and pipeline growth in acne and MASH. Click for this ...

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

“AI doesn’t push back, it doesn’t challenge you, and it doesn’t require emotional presence,” Michael Salas, lead analyst and ...

Key Insights Significant control over Lithium Argentina by retail investors implies that the general public has ...

Moderna MRNA announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in ...

Jacksonville has landed among the top three cities nationally for manufactured housing, with thousands of mobile homes ...

Forests have shifted from absorbing carbon to becoming a net carbon source after 2010 due to extensive losses of tropical ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

A new study reports that bacteria found in the intestines of Japanese tree frogs show remarkable promise in treating colorectal cancer. A research team from the Japan Advanced Institute of Science and ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. ・The company ...

The Bellberry Human Research Ethics Committee formally approved the use of PsyLabs’ psilocybin formulation (NPX5) in Psyence’s clinical trial evaluating psilocybin-assisted psychotherapy for ...